Chart: Sen. Hatch Has Seven Questions About FDA's Structure And Resources
Sen. Orrin Hatch, R-Utah, concluded his speech at the FDA/Food and Drug Law Institute's Annual Meeting on April 22 by asking the audience a series of questions. Some were clearly rhetorical; others emphasized his affection for the dietary supplement industry, but the list highlights what one of the health arena's more powerful actors believes are the thorniest issues facing FDA at the moment. "All of you need to think long and hard about the answers to these questions," Hatch told the audience. "That being said, this is not a test." Below is a transcript of the remarks, with the topic of the questions bolded.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth